BioCryst Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	263.86	-88.88	-226.54	-247.12	-184.06
Depreciation & Amortization	3.49	3.01	2.87	2.25	0.89
Loss (Gain) From Sale of Assets	-4.12	-	-	-	-
Asset Writedown & Restructuring Costs	-	-	1.55	-	-
Loss (Gain) From Sale of Investments	-4.33	-11.47	-10.26	-1.78	-0
Loss (Gain) on Equity Investments	17.55	-	-	-	-
Stock-Based Compensation	85.07	65.41	55.62	44.7	34.64
Other Operating Activities	42.75	67.19	114.03	99.03	-1.75
Change in Accounts Receivable	-36.81	-22.7	-6.1	-21.47	-20.82
Change in Inventory	-1.64	-4.16	-1.45	-12.42	-8.77
Change in Accounts Payable	57.8	14.78	12.53	-22.36	39.41
Change in Unearned Revenue	-	-	-1.23	-0.11	1.28
Change in Other Net Operating Assets	-76.26	-75.2	-36.16	-2.58	-2.99
Operating Cash Flow	347.37	-52.02	-95.14	-161.85	-142.16
Capital Expenditures	-2.47	-1.12	-2.17	-1.35	-2.39
Sale of Property, Plant & Equipment	0.55	-	-	-	-
Divestitures	-6.18	-	-	-	-
Investment in Securities	-5.59	53.72	-129.33	-126.89	18.19
Investing Cash Flow	-13.69	52.59	-131.5	-128.24	15.8
Long-Term Debt Issued	-	-	300	73.07	293.87
Long-Term Debt Repaid	-334.76	-1.7	-262.88	-	-
Net Debt Issued (Repaid)	-334.76	-1.7	37.12	73.07	293.87
Issuance of Common Stock	9.17	3.48	8.68	14.96	65.79
Other Financing Activities	-24.35	-7.54	-13.32	-	-
Financing Cash Flow	-349.93	-5.76	32.49	88.03	359.67
Foreign Exchange Rate Adjustments	1.27	-0.94	0.36	0.57	0.07
Net Cash Flow	-14.99	-6.12	-193.79	-201.5	233.39
Free Cash Flow	344.9	-53.14	-97.31	-163.2	-144.54
Free Cash Flow Margin	39.42%	-11.79%	-29.36%	-60.26%	-91.97%
Free Cash Flow Per Share	1.58	-0.26	-0.51	-0.88	-0.81
Cash Interest Paid	23.74	30.38	22.14	-	0.9
Cash Income Tax Paid	2.8	1.6	1.43	3.54	0.12
Levered Free Cash Flow	256.42	11.95	-67.23	-141.51	-122.67
Unlevered Free Cash Flow	305.72	73.52	0.42	-79.58	-85.61
Change in Working Capital	-56.9	-87.28	-32.4	-58.95	8.12

Source: S&P Global Market Intelligence. Standard template. Financial Sources.